Fig. 1From: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programSurvival analysis for immune-related adverse events. Kaplan-Meier curves for overall survival in patients stratified for the occurrence of immune-related adverse events (a) and with landmark analysis at 6 weeks (b)Back to article page